The global pharmaceutical industry experienced a 30% drop in company filings mentions of regenerative medicine in Q4 2023 compared with the previous quarter, with the highest share accounted for by Bristol-Myers Squibb with 173% year-on-year increase, according to GlobalData’s analysis of over 336 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q4 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Pharma: Filings Trends & Signals Q4 2023

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Notably, regenerative medicine was one of the most frequently referenced themes in Q4 2023, ranking highest in terms of mentions, ahead of social media and edtech, according to GlobalData.

Of the top leading companies in the pharmaceutical industry, Bristol-Myers Squibb had the greatest increase in references for regenerative medicine in Q4 2023, compared with the previous quarter. GlobalData identified 30 regenerative medicine-related sentences in the company's filings - 3% of all sentences - and an increase of 173% in Q4 2023 compared with Q4 2022. Gilead Sciences’s mentions of regenerative medicine dropped by 16% to 27 and AstraZeneca’s by 180% to 14 and BioMarin Pharmaceutical’s by 26% to 14 and Novartis’s by 9% to 10.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for regenerative medicine in Q4 2023 was 96.

For further understanding of GlobalData's Pharma: Filings Trends & Signals Q4 2023, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.